We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Forbius

News List

Bristol Myers Squibb to acquire Forbius expresspharma
August 26, 2020
Forbius’s lead TGF-beta asset, AVID200, is an isoform-selective TGF-beta inhibitor, currently in Phase 1 for oncology and fibrosis.
Forbius Announces the First Patient Dosed in a Phase 1 Oncology Trial of AVID200 americanpharmaceuticalreview
January 10, 2019
Forbius announced the first patient was dosed in a Phase 1 clinical trial with AVID200. The trial will evaluate safety, pharmacokinetics, pharmacodynamics, and antitumor effects of escalating doses of AVID200 in patients with solid tumors.....
CPRIT Awards Forbius Product Development Grant contractpharma
August 28, 2018
Forbius (Formation Biologics) has been awarded a Product Development grant totaling $18.75 million from the Cancer Prevention and Research Institute of Texas (CPRIT).